Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on the Way.
Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.
Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Why Novo Nordisk Stock Is Falling Today
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Citi Sticks to Sell Rating on Hims & Hers (HIMS) Stock as FDA Ruling Clouds Outlook
Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...
Novo Nordisk stock sinks on weight loss drug trial letdown
Novo Nordisk (NVO) shares stumble after the results of the drugmaker's weight loss drug trial showed that patients using the drug dropped only around 15% of their weight, compared to the 25% that was ...
DexCom Stock Drops as Diabetes Devices Maker Gets FDA Warning Letter
DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.
Yahoo Finance6 天
Surprising decision sends weight-loss drug stock reeling
Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues ... up competition involving weight-loss drugs. The Food and Drug Administration two years ...